Executive Director, Business Development, Biologics Consulting Group, Inc., Alexandria, VA.

• Focused on assisting clients in:

  • Strategy planning including business plans, portfolio assessments, competitive positioning, and M&A strategies
• Market development from market sizing, regional strategies, proposal writing, negotiations and contracts
• Manufacturing and capital effectiveness including build versus buy decisions, capacity/capital analysis, and financial modeling.
• Technology assessments including market research, gap analysis, IP valuations, and due diligence.
• Contract services design including organizational gap analysis, forecasting, sales and marketing strategies.

General Manager / Senior Director, Life Technologies Corporation / Invitrogen Corporation.

Successfully captured market share in bioproduction reagent sales through an integrated process development services business with staff of 50, including accountability for P&L, sales, marketing, operations, and R&D. 

• Achieved >40% annual sales growth in cell line development and cell culture optimization services; attained revenue AOP for four of last five years and beat profitability targets each year. 
• Established service partnerships with technology providers and contract manufacturers to expand technical solutions and broaden geographic distribution for process development offerings. 
• Led the sourcing and structuring of strategic research collaborations; served on Joint Steering Committees overseeing operational, business, and legal aspects of program contracts.
• Directed a high performing team responsible for activities from bench to sales and marketing through performance appraisals, career development, and mentoring; earned multiple corporate awards for customer-focus and scientific collaboration.
• Achieved >90% delivery of R&D milestones on schedule; oversaw operations execution of service projects including resource planning, quality systems, business processes and metrics. 
• Grew services revenue from Asian markets 140% by championing market development for key emerging markets (Korea, India, and China) through regional strategy planning and sales activities.
• Established Cellular Medicine business unit, focused on cell culture media, bead-based separation, and analytical characterization products for the industrial cell therapy market.
• Developed multi-generational business plans including new service/product launches, long range forecasting, service lifecycle management, sales planning, and commercialization strategies; business strategies were featured in corporate presentations and highlighted in analyst reviews.

Director, Marketing & Business Development, Life Technologies Corporation / Invitrogen Corporation

Oversaw business development funnel and sales management including territory planning, sales conversion, and contract negotiations for cell culture process development services.

• Increased “book of business” by 500% by defining new services offerings and IP strategies, forming a global sales team, and launching de novo proposal-to-contract sales process.
• Designed and implemented global marketing plans including branding, market positioning, collateral creation, ad placements, conference/seminar schedules, and web strategy.
• Led acquisition of Morphotek technology including due diligence, deal model creation, and BOD presentations; managed outlicensing technology rights for non-core business fields.
• Launched PD-Direct Services, recognized as an Invitrogen “2006 Most Innovative Business Initiative”.

Associate Director, Vaccine Process Engineering, Merck & Co., Inc.

Led team of process engineers in new facility scoping and design for vaccine production.

• Completed Basis of Design for “first in class” HIV/Adenovirus bulk vaccine facility including conceptual facility designs and equipment specifications; clinical strategy changes delayed capital commitment.
• Championed innovative equipment and automation design strategy to achieve standardization and modularity; strategy implemented for 2nd generation Gardasil® fermentation facility.
• Developed in-house and outsourcing strategies for viral vaccine support operations to improve cost basis of operations; Recommendations presented to CEO and senior staff were accepted and implemented;  led conceptual design and equipment specifications for new support facility.
• Provided manufacturing and capital assessments for in licensing for expansion into therapeutic protein markets, including capital effectiveness strategies for cell culture/MAb manufacturing; led industry-wide benchmarking study on process and facility design for cell culture and vaccine manufacturing.
• Participated on internal standards committees focused on bulk facility design, process automation, raw material sourcing, cell substrates, and process validation practices.
• Served as secretary for Vaccine Quality Council reporting to Sr. Vice President of Quality, and secretary for Biologics Process Council reporting to Sr. Vice President of S&T.

Manager / Process Engineer, Vaccine Technology & Engineering, Merck & Co., Inc.

Provided technical management of PedvaxHIB® vaccine manufacturing (>$100MM in annual revenue) and sterile equipment supply for Merck bulk vaccine operations.

• 1. Participated in multiple regulatory inspections of vaccine manufacturing facilities, including CBER (Team-Bio), EMEA, HealthCanada, and WHO.
  2. Led multiple task forces to investigate manufacturing deviations, product testing trends, and yield improvement (totaling >$8MM in productivity gains and 100% deviation reduction).

PEER REVIEWED PUBLICATIONS

1. Carrier et al (2009) "High Throughput Technologies in Bioprocess Development. " In: Encyclopedia of Industrial Biotechnology. M Flickinger (ed), Wiley, New Jersey.
2. Carrier, Gadgil et al (2007) "Increasing performance of mammalian expression platforms." In: Advances in Large Scale BioManufacturing and Scale-Up Production. 2nd ed. E. Langer (ed.), ASM Press, Washington.
3. Carrier, Gayton, Bramble, Shamir (2004) "Process and Facility Design Strategies for Product Launch and Commercialization." In: Advances in Large Scale BioManufacturing and Scale-Up Production. E. Langer (ed.), ASM Press, Washington.
4. Khlebnikov, Carrier, Risa, Skaug, and Keasling (2000) “A regulatable arabinose-inducible gene expression system with consistent control in all cells of a culture.” J. Bacteriol. 182: 7029-7034.
5. Smolke, Carrier, and Keasling (2000) “Coordinated, differential expression of multiple genes through directed mRNA cleavage and stabilization by secondary structures.” Appl. Environ. Microbiol. 66: 5399-5405.
6. Carrier and Keasling (1999) “Investigating autocatalytic gene expression systems through mechanistic modeling.”  J. theor. Biol.  201: 25-36.
7. Carrier and Keasling (1999) “A library of synthetic 5’ secondary structures to manipulate mRNA stability in Escherichia coli.” Biotechnol. Prog. 15: 58-64.
8. Carrier, Jones, and Keasling (1998) “mRNA stability and plasmid copy number effects on gene expression from an inducible promoter system.” Biotechnol. and Bioeng.  59: 666-672.
9. Keasling, Benemann, Pramanik, Carrier, Jones, and Van Dien (1998) “A toolkit for metabolic engineering of bacteria: application to hydrogen production.” In: Biohydrogen. Zaborsk et al. (eds.), Plenum Press, New York, pp. 87-97.  
10. Carrier and Keasling (1997) “Engineering mRNA stability in E. coli by the addition of synthetic hairpins using a 5’ cassette system.” Biotechnol. and Bioeng. 55: 577-580.
11. Carrier and Keasling (1997) “Mechanistic modeling of prokaryotic mRNA decay.” J. theor. Biol. 189: 195-209.
12. Carrier and Keasling (1997) “Controlling messenger RNA stability in bacteria: strategies for engineering gene expression.” Biotechnol. Prog. 13: 699-708.
13. Keasling, Carrier, Jones, Pramanik, and Van Dien (1997) "New tools for metabolic engineering of Escherichia coli." In: Metabolic Engineering. T. Papoutsakis and S. Lee (eds.), Marcel Dekker, New York.